Company profile
MOLECULAR PARTNERS AG
NASDAQ:MOLNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MP-0250 | phase1_2 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03136653 | phase1_2 | completed | 2017-05-23 | 2020-10-12 | Molecular Partners AG | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma |
| NCT05098405 | phase1 | terminated | 2021-10-11 | 2024-01-19 | Molecular Partners AG | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors |
| NCT03084926 | phase1 | completed | 2017-08-08 | 2021-12-13 | Molecular Partners AG | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors |
| NCT02194426 | phase1_2 | completed | 2014-07-01 | 2018-02-20 | Molecular Partners AG | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients |
| NCT04870164 | phase1 | terminated | 2020-11-18 | 2022-01-06 | Molecular Partners AG | Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) |
FDA applications (0)
No records yet.